Stockscreener 앱 받기
3.21
2.72%
0.085
시간 외 거래:
3.44
0.23
+7.17%
전일 마감가:
$3.125
열려 있는:
$3.18
하루 거래량:
8,216
Relative Volume:
0.51
시가총액:
$114.35M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+10.85%
1개월 성능:
+5.25%
6개월 성능:
+34.31%
1년 성능:
+0.00%
1일 변동 폭
$3.12
$3.2799
1주일 범위
$2.845
$3.2799
52주 변동 폭
$2.20
$4.08
Eupraxia Pharmaceuticals Inc Stock (EPRX) Company Profile
EPRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EPRX
Eupraxia Pharmaceuticals Inc
|
3.21 | 114.35M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.32 | 120.86B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
710.00 | 77.62B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
646.64 | 39.62B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
276.19 | 35.50B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.61 | 28.20B | 3.30B | -501.07M | 1.03B | -2.1146 |
Eupraxia Pharmaceuticals Inc Stock (EPRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-11-14 | 개시 | Rodman & Renshaw | Buy |
Eupraxia Pharmaceuticals Inc 주식(EPRX)의 최신 뉴스
Knee Osteoarthritis Pipeline 2024: Key Companies, MOA, ROA, - openPR
Eupraxia Pharmaceuticals (OTCMKTS:EPRXF) Stock Price Down 3.5% – Time to Sell? - Defense World
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Stock Price Down 3.5%Here's Why - MarketBeat
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Shares Down 3.5% – Here’s What Happened - Defense World
Eupraxia Pharmaceuticals Inc - Stockhouse Publishing
Eupraxia Pharmaceuticals (OTCMKTS:EPRXF) Shares Up 1.7% – Still a Buy? - Defense World
Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Sees Significant Increase in Short Interest - Defense World
Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Sees Significant Growth in Short Interest - MarketBeat
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Stock Price Down 1% – Should You Sell? - Defense World
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Trading Down 1%Here's Why - MarketBeat
Eupraxia Pharmaceuticals (OTCMKTS:EPRXF) Stock Price Down 3.3% – What’s Next? - Defense World
Eupraxia Pharmaceuticals (NASDAQ:EPRX) & Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Financial Analysis - Defense World
Eupraxia Pharmaceuticals to Present at 20th ISDE World Congress for Esophageal Diseases - The Eastern Progress Online
Eupraxia Pharmaceuticals Reports Third Quarter 2024 Financial Re - GuruFocus.com
Eupraxia Pharmaceuticals Announces that it has Closed a Non-Brok - GuruFocus.com
Eupraxia Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference - The Eastern Progress Online
Eupraxia Pharmaceuticals Strengthens Senior Management Team - GuruFocus.com
Eupraxia Pharmaceuticals Inc (EPRX-Q) QuotePress Release - The Globe and Mail
Eupraxia Pharma Shares Jump Following Data From Eosinophilic Esophagitis Trial - MarketWatch
Eupraxia's DiffuSphere™ Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six Months - The Malaysian Reserve
Eupraxia's DiffuSphere™ Technology Demonstrates Targeted Drug Re - GuruFocus.com
Eupraxia Pharmaceuticals Inc (EPRX-T) QuotePress Release - The Globe and Mail
Eupraxia Pharmaceuticals to Present at American College of Rheum - GuruFocus.com
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Coverage Initiated at Rodman & Renshaw - Defense World
Eupraxia Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Eupraxia Pharmaceuticals files report with SEC - Investing.com
Eupraxia Pharmaceuticals files report with SEC By Investing.com - Investing.com Australia
RODMAN&RENSHAW Upgrades Eupraxia Pharmaceuticals (NASDAQ:EPRX) to "Strong-Buy" - MarketBeat
Rodman & Renshaw rates Eupraxia stock Buy on 'groundbreaking delivery tech' - Investing.com Canada
Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed", on November 15, 2024 - Canada NewsWire
Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual Meeting - BioSpace
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Now Covered by Rodman & Renshaw - MarketBeat
Eupraxia Pharmaceuticals reports regulatory update - Investing.com
Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed", on November 15, 2024 – Company AnnouncementFT.com - Financial Times
Newswire - KelownaNow
Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis - The Malaysian Reserve
Eupraxia Pharmaceuticals Reports Third Quarter 2024 Financial Results – Company Announcement - Financial Times
Finansavisen - Finansavisen
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Trading Down 5.4%What's Next? - MarketBeat
Eupraxia Pharmaceuticals Reports Third Quarter 2024 Financial Results - Yahoo Finance
Troutman Pepper Advises Eupraxia Pharmaceuticals in Closing of a Non-Brokered Private Placement - Troutman Pepper
Eupraxia Pharmaceuticals Shares Rise After Completing Private Placement - MarketWatch
Eupraxia Pharmaceuticals Announces that it has Closed a Non-Brokered Private Placement of C$44.5 Million - Quantisnow
Eupraxia Pharmaceuticals Inc. - Baystreet.ca
Fennec Pharmaceuticals Inc. - Baystreet.ca
Stocks in play: Eupraxia Pharmaceuticals Inc. - Barchart
Eupraxia Pharmaceuticals to Present at American College of Gastroenterology Annual Scientific Meeting 2024 - Quantisnow
Eupraxia Pharmaceuticals Inc (EPRX) 재무 분석
Eupraxia Pharmaceuticals Inc (EPRX)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
1.03%
자본화:
|
볼륨(24시간):